The "New York Times" is one of the most respected media outlets in the USA for the legalization of cannabis has spoken. In a sensational editorials have been for more than four decades valid prohibition with the times of Prohibition, from 1920 to 1933 is compared, were prohibited as manufacture and sale of alcohol in the United States strictly. It stated cannabis addiction bring compared to alcohol and tobacco dependence "relatively minor problems" with it.
In the editorial, the authors pointed out that pleasure-loving people would have been on drinking during Prohibition, which "law-abiding citizens have been turned into criminals and crime syndicates flourished." In addition, today were young black men, according to FBI statistics clearly bear the brunt of the result is "racist" cannabis prohibition.
According to the U.S. Federal Bureau of Investigation in 2012, there were over 650,000 arrests for possession of marijuana - much more than cocaine, heroin and related drugs. U.S. President Barack Obama had already indicated that poor youth who belong to social minorities, often for marijuana use in jail migrate as better-off peers.
Although the "New York Times" said in her - even for internal editorial controversial - contribution for a ban on the sale of marijuana to adolescents under 21 years. For healthy adults seem "moderate consumption" but to pose a risk, which is why the law adopted by Congress at the federal level more than four decades prohibition was untimely. On the website of the newspaper some readers warned against underestimating the danger of the popular "gateway drug", others called the legalization overdue.
This is, interestingly, not as standard practice moved as cannabis ingredient THC into the center, but the cannabidiol (CBD).
Tetrahydrocannabinol (THC) is always shown as the main active ingredient in cannabis. But cannabis contains 66 different cannabinoids with different modes of action.
For THC the therapeutic use in some situations is difficult by the intoxicating effect. In addition, do not reach all patients with a pure THC preparation - in Switzerland as dronabinol in trade - a satisfactory treatment outcome.
Unlike THC CBD developed no psychoactive “high.” effect.
On the contrary, according to recent studies, CBD should neutralize the psychoactive effect of the THC's or at least slow down. Moreover, it should also have a cancer and anti-inflammatory effect. Already known for some time was its anticonvulsant, anxiolytic, and nausea-relieving effect. In addition, CBD is only slightly toxic and has few side effects, emphasizes the pharmacist Rudolf cautery, a specialist in cannabis at the University of Bern.
For a long time the research around the use of cannabis in medicine, according to cautery has mainly focused on the active ingredient THC. Cannabinoids have been used primarily to treat neurological disorders such as multiple sclerosis or epilepsy, against the side effects of chemotherapy or for chronic pain. The discovery of the CBD and its potency of cannabis gave new impetus to international research, says branding iron. For the natural remedies cannabis thereby always open new research approaches, such as the application in breast cancer, or psychosis. Medicinalcannabis has become increasingly important in recent years.
One consequence of this cannabis research is the introduction of Sativex - a drug with a combination of THC and CBD, may contribute to relief of pain and discomfort in multiple sclerosis.
Cannabis Research: Post-Traumatic Stress Disorder (PTSD)
PTSD is a mental disorder that is usually triggered by the fact that you witness or victim of a particularly harrowing experience; such as war, natural disasters, serious accidents or sexual violence. These incidents cause feelings of helplessness, which can cause extreme stress reactions in the body. It can lead to long-lasting and severe anxiety.
Studies in this area:
1) Increased availability of cannabinoid CB1 receptors in the brain in posttraumatic stress disorder: A positron emission tomography study (Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study - 2013)
This study should explore the previously established effects of PTSD on the endocannabinoid system in animals further. She had set out on exploring through brain scans, the availability of CB1 cannabinoid receptors in the brains of people who suffer from PTSD. It was found that those who were suffering from the disease seemed to have anomalies causing imbalances. This suggests that cannabis may have a potential therapeutic benefit for patients with PTSD and can help to regulate their anxiety. This study has opened the way for further investigations in this area. Published in the journal "Molecular Psychiatry."
THESE STATEMENTS HAVE NOT BEEN EVALUATED BY THE FDA AND ARE NOT INTENDED TO DIAGNOSE, TREAT, OR CURE ANY DISEASE. ALWAYS CHECK WITH YOUR PHYSICIAN BEFORE STARTING A NEW DIETARY SUPPLEMENT PROGRAM.